-
-
-
-
-
-
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
-
-
-
-
-
-
Pfizer executive says China now leads Europe in drug innovation
-
-
-
-
-
-
-
RBC Capital Upgrades Pfizer (PFE) to Sector Perform
-
-
-
-
-
-
-
UBS Reiterates Neutral Rating on Pfizer (PFE)
-
-
-
-
-
-
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
-
-
-
-
-
-
Pfizer (PFE) calls more active than puts into quarter results
-
-
-
-
-
-
-
Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'
-
448,080 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

